Johnson & Johnson, Janssen oppose judgment in US antitrust case over Stelara
MLex Summary: Johnson & Johnson and Janssen Biotech told a US federal judge that CareFirst has not presented enough evidence to support a summary judgment in its antitrust case over Stelara....To view the full article, register now.
Already a subscriber? Click here to view full article